The company's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow. BrainsGate is currently focusing on treatment of acute ischemic stroke, and has developed the ISS, a miniature electrode implanted at the roof of the mouth in a bed side, minimally invasive, local anesthesia procedure comparable to dental treatment. The company has completed clinical trials with promising results, and is currently running a multi-national, randomized, double-blind, sham-controlled pivotal study to assess the safety and efficacy of its treatment for stroke patients in a 24-hour window.